Preview

Rational Pharmacotherapy in Cardiology

Advanced search

OBSERVATIONAL TRAILS IN LIPIDOLOGY

https://doi.org/10.20996/1819-6446-2009-5-2-75-78

Full Text:

Abstract

Approaches to the evaluation of drug efficacy and safety are discussed. The specifics of clinical and observational trails are presented. The trail data on statins efficacy and safety are held up as a model.

About the Author

S. A. Shalnova
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per., 10, Moscow, 101990


References

1. Флетчер Ф., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. Пер. с англ. М.: Медиа Сфера; 1998.

2. HPS Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.

3. Nissen S.E., Nicholls S., Sipahi I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295(13):1556–65.

4. Crouse J.R. 3rd, Grobbee D.E, O'Leary D.H. et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis- -the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004;18(3):231-8.

5. Ridker P.M.. JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Rationale and design of the JUPITER trial. Circulation 2003;108(19):2292– 7.

6. Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008; ;359(21):2195-207.

7. Strom B.L. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA 2004;292(21):2643–6.

8. Johansson S., Ming E.E., Wallander M.A. et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf 2006;15(7):454-61.

9. Кобалава Ж.Д., Склизкова Л.А., Котовская Ю.В. и др. Представления об артериальной гипертонии у пожилых и реальная клиническая практика в России (результаты I этапа российской научно-практической программы АРГУС). Кардиология 2001;(11):31-5

10. Шальнова С.А., Деев А.Д., Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врача кардиолога. Кардиоваск тер профилакт 2006;(1):73–80.

11. Оганов Р.Г., Ольбинская Л.И., Смулевич А.Б. и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология 2004;(1):48-54.

12. Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваск тер профилакт 2006;(6):58-63.

13. García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008; 17(10):943-52.

14. García-Rodríguez LA, González-Pérez A, Stang MR et al. The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008; 17(10):953-961.

15. Goettsch WG, Heintjes EM, Kastelein JJ et al. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006;15(7):435-43.

16. McAfee AT, Ming EE, Seeger JD et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006;15(7):444-53.

17. Kasliwal R, Wilton LV, Cornelius V et al. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug Saf 2007;30(2):157-70.

18. Baigent C et al for the Cholesterol Treatment Trialists' (CTT) Collaborators. Lancet 2005; 366(9493):1267-78.

19. Cziraky MJ, Willey VJ, McKenney JM et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97(8A):61C– 68C.

20. Shepherd J, Vidt DG, Miller E et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107:433–43.


For citation:


Shalnova S.A. OBSERVATIONAL TRAILS IN LIPIDOLOGY. Rational Pharmacotherapy in Cardiology. 2009;5(2):75-78. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-2-75-78

Views: 318


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)